论文部分内容阅读
c-Met为一种由原癌基因MET编码的跨膜受体酪氨酸激酶,是肝细胞生长因子的受体,与多种癌症的不良预后有关。近年来,c-Met抑制剂作为一种对抗癌症的有效策略备受关注。结合汤森路透数据库资源——Thomson Reuters Integrity和Cortellis for Competitive Intelligence,对c-Met在疾病中的作用、相关药物研究进展、适应证、研发机构、交易、专利、文献等情报进行了数据层面的分析。
Met-Met, a transmembrane receptor tyrosine kinase encoded by the proto-oncogene MET, is a receptor for hepatocyte growth factor and is associated with poor prognosis in a variety of cancers. In recent years, c-Met inhibitors have drawn much attention as an effective strategy against cancer. Thomson Reuters Integrity and Cortellis for Competitive Intelligence were used to analyze the role of c-Met in the disease, the progress of research on relevant drugs, indications, R & D institutions, transactions, patents, literature and other information at the data level analysis.